BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 30206411)

  • 1. The role of a monoclonal antibody 11C8B1 as a diagnostic marker of IDH2-mutated sinonasal undifferentiated carcinoma.
    Dogan S; Frosina D; Fayad M; de Oliveira TB; Alemar B; Rosenblum M; Tang LH; Hameed M; Xu B; Ghossein RA; Chute DJ; Weigelt B; Jungbluth AA
    Mod Pathol; 2019 Feb; 32(2):205-215. PubMed ID: 30206411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular epidemiology of IDH2 hotspot mutations in cancer and immunohistochemical detection of R172K, R172G, and R172M variants.
    Dogan S; Frosina D; Geronimo JA; Hernandez E; Mohanty A; Bale T; Hechtman JF; Arcila ME; Hameed MR; Jungbluth AA
    Hum Pathol; 2020 Dec; 106():45-53. PubMed ID: 33017591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical Detection and Molecular Characterization of IDH-mutant Sinonasal Undifferentiated Carcinomas.
    Mito JK; Bishop JA; Sadow PM; Stelow EB; Faquin WC; Mills SE; Krane JF; French CA; Fletcher CDM; Hornick JL; Sholl LM; Jo VY
    Am J Surg Pathol; 2018 Aug; 42(8):1067-1075. PubMed ID: 29683816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA methylation-based classification of sinonasal undifferentiated carcinoma.
    Dogan S; Vasudevaraja V; Xu B; Serrano J; Ptashkin RN; Jung HJ; Chiang S; Jungbluth AA; Cohen MA; Ganly I; Berger MF; Momeni Boroujeni A; Ghossein RA; Ladanyi M; Chute DJ; Snuderl M
    Mod Pathol; 2019 Oct; 32(10):1447-1459. PubMed ID: 31186531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequent IDH2 R172 mutations in undifferentiated and poorly-differentiated sinonasal carcinomas.
    Dogan S; Chute DJ; Xu B; Ptashkin RN; Chandramohan R; Casanova-Murphy J; Nafa K; Bishop JA; Chiosea SI; Stelow EB; Ganly I; Pfister DG; Katabi N; Ghossein RA; Berger MF
    J Pathol; 2017 Aug; 242(4):400-408. PubMed ID: 28493366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrent IDH2 R172X mutations in sinonasal undifferentiated carcinoma.
    Jo VY; Chau NG; Hornick JL; Krane JF; Sholl LM
    Mod Pathol; 2017 May; 30(5):650-659. PubMed ID: 28084339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IDH2 -Mutated Sinonasal Tumors: A Review.
    Alzumaili B; Sadow PM
    Adv Anat Pathol; 2023 Mar; 30(2):104-111. PubMed ID: 36537260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Diagnostic Utility of IDH2 R172 Immunohistochemistry in Tall Cell Carcinoma With Reversed Polarity of the Breast.
    Sasaki E; Iwakoshi A; Satake T; Nakajima K; Kobayashi M; Ando Y; Koshikawa T; Masago K; Honma N; Nishimura R; Kato Y; Ichihara S
    Appl Immunohistochem Mol Morphol; 2022 Nov-Dec 01; 30(10):654-661. PubMed ID: 36222504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IDH2 Mutation Analysis in Undifferentiated and Poorly Differentiated Sinonasal Carcinomas for Diagnosis and Clinical Management.
    Riobello C; López-Hernández A; Cabal VN; García-Marín R; Suárez-Fernández L; Sánchez-Fernández P; Vivanco B; Blanco V; López F; Franchi A; Llorente JL; Hermsen MA
    Am J Surg Pathol; 2020 Mar; 44(3):396-405. PubMed ID: 31876581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarity.
    Pareja F; da Silva EM; Frosina D; Geyer FC; Lozada JR; Basili T; Da Cruz Paula A; Zhong E; Derakhshan F; D'Alfonso T; Wen HY; Giri DD; Hayes MM; Krings G; Bhargava R; Palazzo JP; Rakha EA; Hoda SA; Sanders ME; Collins LC; Schnitt SJ; Chen YY; Weigelt B; Jungbluth AA; Reis-Filho JS; Brogi E
    Mod Pathol; 2020 Jun; 33(6):1056-1064. PubMed ID: 31896809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IDH2 R172 Mutations Across Poorly Differentiated Sinonasal Tract Malignancies: Forty Molecularly Homogenous and Histologically Variable Cases With Favorable Outcome.
    Glöss S; Jurmeister P; Thieme A; Schmid S; Cai WY; Serrette RN; Perner S; Ribbat-Idel J; Pagenstecher A; Bläker H; Keber U; Stadelmann C; Zechel S; Johann PD; Hasselblatt M; Paulus W; Thomas C; Dohmen H; Baumhoer D; Frank S; Agaimy A; Schüller U; Vasudevaraja V; Snuderl M; Liu CZ; Pfister DG; Jungbluth AA; Ghossein RA; Xu B; Capper D; Dogan S
    Am J Surg Pathol; 2021 Sep; 45(9):1190-1204. PubMed ID: 34265800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IDH1/2 Mutations in Sinonasal Undifferentiated Carcinomas : Previously Undescribed IDH2 R172K and R140x Variants.
    Kakkar A; Rathor A; Ashraf SF; Singh V; Sikka K; Jain D
    Am J Surg Pathol; 2022 Sep; 46(9):1284-1290. PubMed ID: 35486703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.
    Kato Y
    Brain Tumor Pathol; 2015 Jan; 32(1):3-11. PubMed ID: 25324168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel monoclonal antibody SMab-2 recognizes endogenous IDH2-R172S of chondrosarcoma.
    Liu X; Ogasawara S; Kaneko MK; Oki H; Hozumi Y; Goto K; Takagi M; Kato Y
    Biochem Biophys Res Commun; 2015 Apr; 459(4):636-42. PubMed ID: 25753205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1.
    Liu X; Kato Y; Kaneko MK; Sugawara M; Ogasawara S; Tsujimoto Y; Naganuma Y; Yamakawa M; Tsuchiya T; Takagi M
    Cancer Med; 2013 Dec; 2(6):803-14. PubMed ID: 24403254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemistry using monoclonal antibody MsMab-2 is useful to detect IDH1 R132L in intrahepatic cholangiocarcinoma.
    Hayashi A; Misumi K; Shibahara J; Kokudo N; Kato Y; Fukayama M
    Pathol Int; 2016 Oct; 66(10):578-582. PubMed ID: 27595804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Solid papillary breast carcinomas resembling the tall cell variant of papillary thyroid neoplasms (solid papillary carcinomas with reverse polarity) harbour recurrent mutations affecting IDH2 and PIK3CA: a validation cohort.
    Lozada JR; Basili T; Pareja F; Alemar B; Paula ADC; Gularte-Merida R; Giri DD; Querzoli P; Cserni G; Rakha EA; Foschini MP; Reis-Filho JS; Brogi E; Weigelt B; Geyer FC
    Histopathology; 2018 Aug; 73(2):339-344. PubMed ID: 29603332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations.
    Kato Kaneko M; Ogasawara S; Kato Y
    Tohoku J Exp Med; 2013 Jun; 230(2):103-9. PubMed ID: 23782684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
    Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
    J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone.
    Chen S; Fritchie K; Wei S; Ali N; Curless K; Shen T; Brini AT; Latif F; Sumathi V; Siegal GP; Cheng L
    Hum Pathol; 2017 Jul; 65():239-246. PubMed ID: 28552826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.